Introduction
============

The circadian clock is an internal time keeping system that allows organisms to adapt physiological and behavioral processes to environmental light/dark cycles ([@ref-10]). In mammals, the master clock is located in the suprachiasmatic nucleus (SCN) ([@ref-2]). The SCN exhibits endogenous rhythms and controls circadian rhythms in peripheral tissues such as liver, heart and kidney ([@ref-16]). In addition, to receiving the information transmitted by neuronal and humoral pathways from the SCN, the peripheral tissues also have an internal timing system, and several clock genes such as transcriptional activators (e.g., *Clock* and *Bmal1*) and repressors (e.g., *Per1* and *Per2*) form a transcriptional−translational feedback loop ([@ref-29]). The core clock transcription factor, CLOCK, coupled with BMAL1 activates the transcription of repressors as well as clock-controlled genes (CCGs). There is one additional regulatory feedback loop, in which the stabilizing feedback loop relies on alternate repression by REV-ERBα and activation by RORα ([@ref-12]; [@ref-21]).

The liver is currently the most extensively studied peripheral tissue with respect to circadian rhythms. Recent studies have suggested that CLOCK contribute to a wide variety of physiological processes in the liver, such as cell proliferation ([@ref-17]), cell division ([@ref-15]), and obesity ([@ref-14]; [@ref-26]). [@ref-15] found that, several key genes involved in cell-cycle progression, including *Wee1* and *Cdc2*, were direct targets of the CLOCK--BMAL1 complex. [@ref-20] revealed that CLOCK was involved in the transcriptional regulation of many circadian output genes, based on microarray analyses using liver RNA isolated from *Clock* mutant mice. However, those studies were mainly focused on the protein-encoding mouse transcriptome. It is necessary to identify a more complete cohort of genes that are post-transcriptionally regulated by CLOCK to fully understand the molecular mechanisms by which clock genes affect physiological processes in the liver.

MicroRNAs (miRNAs), short non-coding RNA molecules, can regulate gene expression by repressing gene transcription by binding to the 3′ untranslated region (3′UTR) of target mRNAs ([@ref-11]). Several studies have demonstrated that circadian miRNAs, which have been identified by microarray-based expression profiling or miRNA-sequencing (miR-seq), are involved in metabolic homeostasis and cell cycles ([@ref-18]; [@ref-27]).

In the present study, we performed a microarray analyses of miRNAs in the liver of *Clock*^Δ19^ mutant mice to identify putative CLOCK-regulated miRNAs. Then we conducted bioinformatic analyses to identify the target genes of differentially expressed miRNAs and analyzed the pathways in which they are involved. Our results provide a unique basis for further unraveling of the role of putative CLOCK-regulated miRNAs in the liver.

Materials and Methods
=====================

Ethics statement
----------------

All animal procedures used in this study were conducted in compliance with animal protection protocol as approved by the Institutional Animal Care and Use Committee in China. All the experimental procedures were approved by the Committees of Animal Ethics and Experimental Safety of China Astronaut Research and Training Center, and the ethical approval number was "2012-045."

Animals
-------

*Clock* mutant mice (*Clock*^Δ19^) were acquired from the Institute of Psychology, Chinese Academy of Sciences, Beijing, China. All male mice at 6−8 weeks of age used in this study were individually caged and maintained under IVC conditions with 12 h light/dark cycle, lights-on at 07:00 h and free access to food and water for 2 weeks before using. At 09:00 h zeitgeber time 2 (ZT2), 21:00 h zeitgeber time 14 (ZT14) on the first day after 2 weeks adaptation period, three animals of each group were sacrificed by dry ice. The liver was isolated, quickly frozen and stored in liquid nitrogen. For analyzing genes expression by real-time PCR, *Clock* mutant mice and their wild type controls (5 mice of each group per time point) were killed every 4 h across 26 h at 09:00 h (ZT2), 13:00 h (ZT6), 17:00 h (ZT10), 21:00 h (ZT14), 01:00 h (ZT18), 05:00 h (ZT22) and 09:00 h of the following day (ZT2).

Total RNA isolation and microarray hybridization
------------------------------------------------

According to illumina's protocol, the three RNA samples at each time point were mixed and isolated using the mirVana miRNA extraction Kit (Ambion, Austin, TX, USA). RNA labeling, microarray hybridization and data processing were analyzed by Shanghai OE Biotech. Co. Ltd., Briefly, RNA labeled and hybridized using the Agilent mouse 4 × 44 K microRNA microarray. Hybridization signals were detected with an Agilent DNA microarray scanner G2565BA, and scan images were analyzed using Agilent feature extraction software. Data is analyzed using Agi4×44PreProcess (Agilent Technologies, Santa Clara, CA, USA). The Fold Change Absolute larger than or equal to two was considered to have an evident difference.

MicroRNA target prediction and functional annotation
----------------------------------------------------

The predicted targets of miRNAs (both changed at two time points with FCA ≥ 2) were analyzed by miRwalk ([@ref-1]), the predicted targets obtained from at least four programs in miRanda, miRDB, RNAhybrid, PICTAR 5, PITA and Targetscan were regarded as the putative target genes. Then the putative target genes were integrated into David (DAVID 6.7; <https://david-d.ncifcrf.gov/>) to analyze Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway ([@ref-7], [@ref-8]). Based on the interactions of miRNAs and target genes, the miRNA function network was built.

Integration of protein--protein interaction network and module analysis
-----------------------------------------------------------------------

To evaluate the interactive relationships among prediction target genes, all genes were mapped to an online tool, STRING (Version 10.0) ([@ref-25]), to evaluate the Protein−protein interaction (PPI) information. The experimentally validated interactions with a combined score \>0.4 were considered significant. Then, the Molecular Complex Detection (MCODE), one plug-in unit of Cytoscape ([@ref-24]) was utilized to screen the modules of PPI network. The criteria were: for MCODE scores \>5 and number of nodes \>10. Moreover, the function and pathway enrichment analysis of the genes in the modules were performed. *p* \< 0.05 was regarded as significant differences.

Real time quantitative polymerase chain reaction
------------------------------------------------

To validate the expression of miRNAs of interest, total RNA was extracted from liver tissue using the TRIzol regent (Cat. \#15596026; Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Then the RNA was reversed and poly A tailed using PrimeScript™ miRNA qPCR starter kit ver. 2.0 (Cat. \# RR718; TaKaRa, Shiga, Japan). The cDNA was used as the template for the qPCR, which was performed using the SYBR^®^ Premix Ex Taq™II (Cat. \#DRR820A; TaKaRa, Shiga, Japan).The sequences of primers used for qRT-PCR were presented in [Table 1](#table-1){ref-type="table"}. Amplification data were analyzed using the comparative threshold (2^−ΔΔCt^) method after normalization to U6.
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###### The primers used for qRT-PCR analysis.
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  Gene       Forward sequences (5′--3′)   Reverse sequences (5′--3′)
  ---------- ---------------------------- ----------------------------
  U6         CTCGCTTCGGCAGCACATATACT      ACGCTTCACGAATTTGCGTGTC
  miR-195    CGTAGCAGCACAGAAATATTGGC      
  miR-338    AACAATATCCTGGTGCTGAGTG       
  miR-340    CGGTCCGTCTCAGTTACTTTATAG     
  miR-374    CGGATATAATACAACCTGCTAAGTG    
  miR-669d   ACTTGTGTGTGCATGTATATGT       

**Note:**

The reverse primer of miRNAs referred to the manual of Prime Script™ miRNA qPCR starter Kit ver. 2.0 (Cat. \#RR718; TaKaRa, Shiga, Japan).

Results
=======

Identification of differentially expressed miRNA
------------------------------------------------

A total of 194 miRNAs were identified in the liver of *Clock* mutant mice compared to WT mice ([Table S1](#supp-1){ref-type="supplementary-material"}) at ZT2, of which the expression of 61 miRNAs (35 downregulated miRNAs and 26 upregulated miRNAs) differed by at least 1 fold (log~2~^fold\ change^ ≥ 1) ([Fig. 1A](#fig-1){ref-type="fig"}). Among 157 miRNAs ([Table S2](#supp-2){ref-type="supplementary-material"}), 24 downregulated and 33 upregulated miRNAs were differentially expressed between *Clock* mutant and control mice at ZT14 ([Fig. 1B](#fig-1){ref-type="fig"}). Of these miRNAs, miR-100, miR-221, miR-34a, miR-340-3p, miR-338-5p, miR-497, miR-195, miR-423-5p, miR-374, miR-669d, miR-429, miR-532-5p, miR-455 and miR-802, were differentially expressed at both time points ([Fig. 1C](#fig-1){ref-type="fig"}). Next, these 14 conserved miRNAs were evaluated by downstream target prediction and biological annotation enrichment analyses.

![Differentially expressed miRNAs in the liver of *Clock*^Δ19^ mutant mice.\
(A) miRNAs changed in clock mutant mice compared with WT mice at ZT2. (B) miRNAs changed in *Clock* mutant mice compared with WT mice at ZT14. (C) miRNAs altered both in ZT2 and ZT14 under *Clock* mutant conditions. FC was the meaning of Fold Change. The value exceeds and below zero were considered up and down, respectively. All selected miRNAs were FCA ≥ 2.](peerj-07-8119-g001){#fig-1}

miRNA regulatory network
------------------------

The putative target genes of the 14 differentially expressed miRNAs were predicted by miRwalk to obtain a more comprehensive understanding of their roles in the liver. Of these 1,781 putative miRNA-mRNA pairs, several core circadian clock gene-miRNA pairs (miR-340-3p targeting *Clock*, *Per1*, *Cry2*; miR-669d targeting *Per2*; miR-374 targeting *Per3* and miR-338-5p targeting *Nr1d1*) were identified ([Table S3](#supp-3){ref-type="supplementary-material"}; [Fig. 2](#fig-2){ref-type="fig"}). Twenty four genes were identified as potential targets of three miRNAs. Notably, the Nrn1 gene was regulated by four miRNAs: miR-34a, miR-374, miR-423-5p, and miR-669d. In addition, miR-195, miR-338-5p, miR-374 and miR-497 together regulate the *Hoxa10* gene ([Fig. 2](#fig-2){ref-type="fig"}).

![The main miRNA-target mRNA regulatory network of 14 miRNAs.\
The yellow ellipses indicate miRNAs, others are genes. Red hexagons represent circadian genes. Blue rectangles represent the genes, which are controlled by three miRNAs; triangles in pink indicate the genes, which are controlled by four miRNAs.](peerj-07-8119-g002){#fig-2}

Gene ontology and KEGG pathway analyses of the differentially expressed miRNA targets
-------------------------------------------------------------------------------------

For functional enrichment analyses of miRNAs, we uploaded the full list of target genes to DAVID 6.7 and extracted clustering information of the biological process (BP), cellular component (CC), molecular function (MF), and KEGG pathway categories. The BP category were mostly involved in regulation of transcription, regulation of RNA metabolic process, and intracellular signaling cascade ([Fig. 3A](#fig-3){ref-type="fig"}). As shown in [Fig. 3B](#fig-3){ref-type="fig"}, CC category analyses revealed that the target genes were highly associated with plasma membrane, membrane-enclosed lumen, and intracellular organelle lumen. In the MF category, the three most enriched terms were ion binding, cation binding and metal ion binding ([Fig. 3C](#fig-3){ref-type="fig"}). The three most enriched KEGG pathways were the pathways in cancer, PI3K-Akt signaling pathway, and the MAPK signaling pathway ([Table 2](#table-2){ref-type="table"}).

![Enriched gene ontology terms of predicted targets of 14 differentially expressed miRNAs in the liver of *Clock* mutant mice.\
(A) Biological process. (B) Cellular component. (C) Molecular function.](peerj-07-8119-g003){#fig-3}
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###### The KEGG pathway of the potential target genes.

The KEGG pathway were analyzed by the predicted target genes of 14 differentially expressed miRNAs.
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  Term                                                       Count   *p* Value   Genes
  ---------------------------------------------------------- ------- ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pathways in cancer                                         54      4.13E−05    E2F2, ADCY1, FGF7, PPARG, LPAR4, FOXO1, LPAR1, PTEN, CCNE1, MAX, FOS, RALA, PLCB1, AKT3, PTGER4, ROCK2, RUNX1T1, LEF1, STK4, VEGFC, EP300, CRKL, HIF1A, GNB2, GNAQ, JUN, MAPK3, MAPK9, GNAS, WNT5A, GNAI3, BCL2L1, TCF7L2, IGF1R, RAC1, RUNX1, TRAF3, AXIN1, COL4A3, BMP2, MAP2K1, CBL, SMAD3, RAF1, HGF, FZD5, KITL, FZD4, FZD7, NRAS, CBLB, CDKN1A, LAMA5, GNG10
  PI3K-Akt signaling pathway                                 42      0.004263    CRTC2, FGF7, PPP2R5A, CSF1, LPAR4, BCL2L1, LPAR1, PTEN, CCNE1, IGF1R, COMP, PPP2CA, RAC1, CREB3L1, ANGPT1, PDGFD, COL11A1, INSR, PPP2R2D, AKT3, COL4A3, SGK1, MAP2K1, ITGA1, RAF1, HGF, ITGA4, KITL, COL5A2, IL6RA, NRAS, VEGFC, CDKN1A, GNB2, CCND2, LAMA5, GNG10, MAPK3, YWHAQ, EFNA4, COL24A1, IL2
  MAPK signaling pathway                                     37      2.07E−04    IL1R1, FGF7, TNF, MRAS, DUSP10, CACNB2, CACNB4, MAX, FOS, MAP3K2, MAP3K1, RAC1, MAP3K8, PPP3CA, MAP2K6, AKT3, NFATC1, NTF3, MAP2K1, TAOK1, NF1, MAP2K4, RAF1, STK4, NRAS, CRKL, MAPK12, DUSP1, RPS6KA2, JUN, MAPK3, MAPK9, RAP1B, DUSP8, GADD45A, CACNA1D, DUSP6
  HTLV-I infection                                           35      0.004332    WNT5A, CRTC2, E2F2, IL1R1, ADCY1, TNF, MRAS, ITGB2, BCL2L1, MYBL2, MSX2, FOS, MAP3K1, PPP3CA, AKT3, TBPL1, NFATC1, KAT2B, MAP2K4, SMAD3, FZD5, FZD4, FZD7, NRAS, CDKN1A, SLC25A31, MSX1, ATF3, EP300, MAD2L1, CCND2, ETS1, JUN, ETS2, IL2
  Proteoglycans in cancer                                    34      2.73E-05    WNT5A, CAV2, CAV1, TNF, MRAS, CAMK2G, LUM, SDC4, HOXD10, IQGAP1, SDC2, IGF1R, ANK2, RAC1, FRS2, CAMK2A, AKT3, MAP2K1, ROCK2, CBL, RAF1, HGF, FZD5, DDX5, FZD4, PPP1CB, FZD7, NRAS, CDKN1A, CBLB, HIF1A, MAPK12, MAPK3, HBEGF
  Focal adhesion                                             34      4.10E−05    CAV2, CAV1, PTEN, VCL, IGF1R, PAK7, ARHGAP5, PAK4, COMP, RAC1, PDGFD, COL11A1, AKT3, COL4A3, VAV3, ACTN4, MAP2K1, ROCK2, ITGA1, RAF1, ACTN1, HGF, ITGA4, COL5A2, PPP1CB, VEGFC, CRKL, CCND2, LAMA5, JUN, MAPK3, MAPK9, RAP1B, COL24A1
  Rap1 signaling pathway                                     33      1.86E−04    ADCY1, FGF7, GNAI3, CSF1, MRAS, LPAR4, ITGB2, LPAR1, IGF1R, CNR1, RAC1, RALA, ANGPT1, PDGFD, PLCB1, INSR, AKT3, MAP2K6, MAP2K1, RAF1, HGF, KITL, DOCK4, NRAS, VEGFC, CRKL, GNAQ, MAPK12, ID1, MAPK3, GNAS, RAP1B, EFNA4
  Ras signaling pathway                                      31      0.002606    FGF7, CSF1, MRAS, ARF6, BCL2L1, IGF1R, PAK7, PAK4, RAC1, RALA, ANGPT1, PDGFD, INSR, AKT3, MAP2K1, NF1, RAF1, HGF, STK4, KITL, NRAS, VEGFC, GNB2, ETS1, GNG10, ETS2, MAPK3, MAPK9, PLA2G6, RAP1B, EFNA4
  cAMP signaling pathway                                     30      4.80E−04    ADCY1, GNAI3, CAMK2G, PDE3B, SOX9, FOS, RAC1, PDE4B, CREB3L1, SUCNR1, CAMK2A, AKT3, NFATC1, VAV3, MAP2K1, ROCK2, HTR4, RAF1, CFTR, GRIA4, ATP1A2, PPP1CB, EP300, GRIA2, JUN, MAPK3, MAPK9, GNAS, RAP1B, CACNA1D
  Endocytosis                                                29      0.082734    CAV2, CAV1, CHMP4B, CAPZA2, SNX2, ARF6, SNX4, EEA1, CLTC, AMPH, IGF1R, ARPC2, SH3GLB1, WWP1, SPG20, DNAJC6, VPS4A, WIPF1, IQSEC2, CBL, KIF5C, PSD3, SMAD3, A230046K03RIK, ARPC1A, CBLB, RAB35, WASL, RAB10
  Oxytocin signaling pathway                                 28      6.06E−05    ADCY1, GNAI3, CAMK2G, CACNB2, CACNB4, KCNJ12, KCNJ14, FOS, PPP3CA, PLCB1, CAMK2A, NFATC1, MAP2K1, ROCK2, PRKAB2, PRKAB1, RAF1, PPP1CB, KCNJ5, CD38, NRAS, CDKN1A, GNAQ, JUN, MAPK3, GNAS, GUCY1B3, CACNA1D
  Regulation of actin cytoskeleton                           27      0.012774    FGF7, MRAS, IQGAP3, ITGB2, IQGAP1, VCL, PAK7, ARPC2, PAK4, RAC1, PDGFD, VAV3, MAP2K1, ACTN4, ROCK2, ITGA1, ACTN1, RAF1, ITGA4, PPP1CB, ARPC1A, NRAS, CRKL, MAPK3, CYFIP1, WASL, PIP4K2B
  Dopaminergic synapse                                       26      2.50E−05    GNAI3, PPP2R5A, CAMK2G, KIF5C, MAOB, GRIA4, PPP1CB, KCNJ5, FOS, GNAQ, GRIA2, GNB2, MAPK12, PPP2CA, GNG10, SLC18A2, CREB3L1, MAPK9, GNAS, PPP3CA, PLCB1, CACNA1D, CAMK2A, CLOCK, AKT3, PPP2R2D
  FoxO signaling pathway                                     26      2.50E−05    SGK1, MAP2K1, PRKAB2, PRKAB1, FOXO1, SMAD3, RAF1, HOMER1, SIRT1, STK4, PTEN, IL10, NRAS, IGF1R, TNFSF10, PLK4, CDKN1A, EP300, MAPK12, CCND2, MAPK3, MAPK9, KLF2, GADD45A, INSR, AKT3
  Signaling pathways regulating pluripotency of stem cells   26      4.19E−05    WNT5A, BMI1, MEIS1, ACVR1C, ACVR1B, IGF1R, AKT3, AXIN1, BMP2, MAP2K1, MYF5, SMAD5, SMAD3, RAF1, FZD5, FZD4, FZD7, NRAS, ACVR2A, MAPK12, ID1, MAPK3, ID4, BMPR1B, ZFHX3, BMPR1A
  Axon guidance                                              25      3.80E−05    GNAI3, PLXNA2, EPHB2, SEMA5A, PAK7, UNC5B, SEMA3F, PAK4, SEMA3E, RAC1, PPP3CA, SEMA3A, LRRC4, ROCK2, NTNG1, SLIT2, SLIT3, NCK2, EPHA4, SEMA6A, NRAS, EPHA7, RND1, MAPK3, EFNA4
  Hippo signaling pathway                                    25      4.73E−04    WNT5A, BTRC, GDF6, ITGB2, TCF7L2, LATS2, CTGF, PPP2CA, DLG3, FBXW11, PPP2R2D, AXIN1, BMP2, SMAD3, LEF1, FZD5, SNAI2, FZD4, PPP1CB, FZD7, ID1, CCND2, YWHAQ, BMPR1B, BMPR1A
  Wnt signaling pathway                                      24      4.22E−04    WNT5A, ROCK2, CAMK2G, BTRC, LEF1, FZD5, DAAM2, TCF7L2, FZD4, FZD7, EP300, SFRP1, CCND2, JUN, RAC1, MAPK9, WIF1, PPP3CA, RUVBL1, PLCB1, CAMK2A, FBXW11, AXIN1, NFATC1
  Transcriptional misregulation in cancer                    24      0.003952    BMI1, CCNT2, NFKBIZ, LDB1, PPARG, RUNX1T1, FOXO1, TSPAN7, BCL2L1, AFF1, DDX5, MEIS1, MYCN, IGF1R, MAX, CDKN1A, FLI1, SP1, CCND2, GOLPH3, ETV6, RUNX1, HPGD, MLLT3
  TGF-beta signaling pathway                                 23      2.58E−07    BMP2, TNF, LTBP1, E2F5, SMAD7, GDF6, SMAD6, SMAD5, SMAD3, ACVR1C, ACVR2A, ACVR1B, EP300, SP1, ID1, PPP2CA, MAPK3, TGIF1, ID4, BMPR1B, PITX2, BMPR1A, TFDP1
  cGMP-PKG signaling pathway                                 23      0.011286    ADCY1, GNAI3, MAP2K1, ROCK2, RAF1, PDE3B, ATP1A2, PRKG1, PPP1CB, KCNMB2, MEF2D, SLC25A31, GNAQ, MAPK3, ADRA1B, CREB3L1, GUCY1B3, PPP3CA, PLCB1, INSR, CACNA1D, AKT3, NFATC1
  Adrenergic signaling in cardiomyocytes                     22      0.005094    ADCY1, GNAI3, PPP2R5A, CAMK2G, CACNB2, ATP1A2, CACNB4, PPP1CB, TPM1, GNAQ, MAPK12, PPP2CA, MAPK3, KCNE1, ADRA1B, CREB3L1, GNAS, PLCB1, CACNA1D, CAMK2A, AKT3, PPP2R2D
  Protein processing in endoplasmic reticulum                22      0.017745    SEC23A, RAD23B, SEC24A, DERL1, SYVN1, UBE4B, RNF185, DNAJB12, STUB1, SSR1, UBE2E3, BAK1, HSPA4L, ERN1, SIL1, MAPK9, AMFR, SEC24C, SEC24D, SAR1A, SEL1L, DNAJA2
  T cell receptor signaling pathway                          21      1.03E−04    VAV3, TNF, MAP2K1, CBL, CTLA4, RAF1, IL10, NCK2, NRAS, FOS, PAK7, CBLB, MAPK12, JUN, PAK4, MAPK3, MAP3K8, PPP3CA, AKT3, IL2, NFATC1
  Insulin signaling pathway                                  21      0.004921    MAP2K1, CBL, PRKAB2, PHKA1, PRKAB1, ACACA, FOXO1, PDE3B, RAF1, PPP1CB, NRAS, PPP1R3D, CBLB, CRKL, PPP1R3F, MAPK3, FASN, MAPK9, PTPN1, INSR, AKT3
  GnRH signaling pathway                                     20      2.91E−05    ADCY1, MAP2K1, CAMK2G, MAP2K4, RAF1, PRKCD, NRAS, GNAQ, MAPK12, MAP3K2, JUN, MAP3K1, MAPK3, MAPK9, HBEGF, GNAS, PLCB1, CACNA1D, CAMK2A, MAP2K6
  Circadian entrainment                                      20      1.37E−04    ADCY1, GNAI3, CAMK2G, GRIA4, PRKG1, KCNJ5, FOS, GNAQ, GRIA2, GNB2, GNG10, MAPK3, PER2, PER1, GNAS, GUCY1B3, PER3, PLCB1, CACNA1D, CAMK2A
  Melanogenesis                                              20      1.57E−04    WNT5A, ADCY1, GNAI3, MAP2K1, CAMK2G, LEF1, RAF1, FZD5, KITL, FZD4, TCF7L2, FZD7, NRAS, EP300, GNAQ, MAPK3, CREB3L1, GNAS, PLCB1, CAMK2A
  Sphingolipid signaling pathway                             20      0.002751    GNAI3, TNF, SPTLC1, MAP2K1, PPP2R5A, ROCK2, RAF1, SGMS1, PTEN, NRAS, S1PR3, GNAQ, MAPK12, PPP2CA, RAC1, MAPK3, MAPK9, PLCB1, AKT3, PPP2R2D
  Hepatitis B                                                20      0.015866    E2F2, TNF, MAP2K1, MAP2K4, RAF1, PTEN, DDX58, NRAS, FOS, CCNE1, CDKN1A, EP300, JUN, MAP3K1, MAPK3, YWHAQ, CREB3L1, MAPK9, AKT3, NFATC1
  ErbB signaling pathway                                     19      8.50E−05    MAP2K1, CAMK2G, CBL, MAP2K4, RAF1, NCK2, NRAS, PAK7, CBLB, CDKN1A, CRKL, EREG, JUN, PAK4, MAPK3, HBEGF, MAPK9, CAMK2A, AKT3
  Chagas disease (American trypanosomiasis)                  19      7.62E−04    ADCY1, TNF, GNAI3, MAP2K4, SMAD3, IL10, FOS, GNAQ, MAPK12, JUN, PPP2CA, MAPK3, IL12A, MAPK9, GNAS, PLCB1, AKT3, PPP2R2D, IL2
  Retrograde endocannabinoid signaling                       19      7.62E−04    GABRG1, ADCY1, GABRA2, GNAI3, GABRA1, GRIA4, KCNJ5, SLC17A6, NAPEPLD, GNAQ, GRIA2, GNB2, MAPK12, CNR1, GNG10, MAPK3, MAPK9, PLCB1, CACNA1D
  Cholinergic synapse                                        19      0.002276    ADCY1, GNAI3, MAP2K1, CAMK2G, KCNJ12, KCNJ14, NRAS, FOS, GNAQ, GNB2, GNG10, MAPK3, CHRNA4, CREB3L1, SLC5A7, PLCB1, CACNA1D, CAMK2A, AKT3
  Neurotrophin signaling pathway                             19      0.005293    MAP2K1, NTF3, CAMK2G, RAF1, PRKCD, NRAS, CRKL, MAPK12, PRDM4, RPS6KA2, JUN, MAP3K1, RAC1, MAPK3, MAPK9, RAP1B, FRS2, CAMK2A, AKT3
  Lysosome                                                   19      0.005293    AGA, CTSZ, AP4E1, AP1B1, CLTC, GNS, NPC1, AP1S2, LAPTM5, LAMP3, GNPTAB, AP3M1, AP3B2, GALC, GAA, AP3D1, GGA2, CLN5, AP3B1
  AMPK signaling pathway                                     19      0.008048    SCD1, CRTC2, PPP2R5A, PPARG, PRKAB2, PRKAB1, ACACA, FOXO1, CFTR, SIRT1, ADIPOQ, IGF1R, PPP2CA, FASN, CREB3L1, RAB10, INSR, AKT3, PPP2R2D
  Vascular smooth muscle contraction                         19      0.008048    ADCY1, MAP2K1, ROCK2, CALD1, PRKCH, RAF1, PRKG1, PRKCD, PPP1CB, KCNMB2, GNAQ, MAPK3, ADRA1B, PLA2G6, GNAS, GUCY1B3, CALCRL, PLCB1, CACNA1D
  Adherens junction                                          18      2.24E−05    ACTN4, LEF1, ACTN1, SMAD3, SNAI2, TCF7L2, SNAI1, IQGAP1, VCL, IGF1R, TJP1, EP300, RAC1, MAPK3, WASL, PTPN1, YES1, INSR
  Oocyte meiosis                                             18      0.004111    ADCY1, MAP2K1, PPP2R5A, CPEB3, CAMK2G, BTRC, PPP1CB, IGF1R, CCNE1, MAD2L1, SLK, RPS6KA2, PPP2CA, MAPK3, YWHAQ, PPP3CA, CAMK2A, FBXW11
  Amoebiasis                                                 18      0.007719    COL4A3, IL1R1, ADCY1, TNF, ACTN4, ACTN1, ITGB2, COL5A2, IL10, VCL, GNAQ, LAMA5, IL12A, GNAS, SERPINB13, PLCB1, COL24A1, COL11A1
  Platelet activation                                        18      0.022312    ADCY1, GNAI3, ROCK2, PTGS1, PRKG1, PPP1CB, COL5A2, GNAQ, MAPK12, FGA, MAPK3, GNAS, GUCY1B3, RAP1B, PLCB1, COL24A1, COL11A1, AKT3
  Serotonergic synapse                                       18      0.023857    GNAI3, MAP2K1, PTGS1, MAOB, SLC6A4, HTR4, RAF1, KCNJ5, NRAS, APP, GNAQ, GNB2, GNG10, MAPK3, SLC18A2, GNAS, PLCB1, CACNA1D
  Tight junction                                             18      0.037031    GNAI3, ACTN4, MPDZ, MRAS, PRKCH, ACTN1, AMOTL1, PRKCD, PTEN, CLDN15, NRAS, TJP1, PPP2CA, ASH1L, RAB13, YES1, AKT3, PPP2R2D
  Estrogen signaling pathway                                 17      0.003032    ADCY1, GNAI3, MAP2K1, RAF1, PRKCD, KCNJ5, NRAS, FOS, GNAQ, SP1, JUN, MAPK3, CREB3L1, HBEGF, GNAS, PLCB1, AKT3
  Glucagon signaling pathway                                 17      0.003732    CRTC2, CAMK2G, PHKA1, PRKAB2, PRKAB1, ACACA, PDE3B, FOXO1, SIRT1, EP300, GNAQ, CREB3L1, GNAS, PPP3CA, PLCB1, CAMK2A, AKT3
  Choline metabolism in cancer                               17      0.004129    MAP2K1, CHKB, RAF1, NRAS, FOS, HIF1A, SP1, DGKE, JUN, DGKG, MAPK3, RAC1, MAPK9, SLC5A7, WASL, PDGFD, AKT3
  Insulin resistance                                         17      0.009491    CRTC2, TNF, PRKAB2, PRKAB1, FOXO1, PRKCD, PTEN, PPP1CB, PPP1R3D, RPS6KA2, MLX, CREB3L1, MAPK9, OGT, PTPN1, INSR, AKT3
  Glutamatergic synapse                                      17      0.014278    SLC38A3, ADCY1, GNAI3, SLC38A2, GRIK5, GRIA4, HOMER1, SLC17A6, GNAQ, GRIA2, GNB2, GNG10, MAPK3, GNAS, PPP3CA, PLCB1, CACNA1D
  Ubiquitin mediated proteolysis                             17      0.077448    SYVN1, UBE3A, BTRC, UBE4B, CBL, BIRC6, UBE2H, HERC2, STUB1, CUL3, UBE2E3, CBLB, MAP3K1, WWP1, UBE2M, TRIM32, FBXW11
  Prostate cancer                                            16      0.002635    E2F2, MAP2K1, FOXO1, RAF1, LEF1, PTEN, TCF7L2, NRAS, IGF1R, CCNE1, CDKN1A, EP300, MAPK3, CREB3L1, PDGFD, AKT3
  Thyroid hormone signaling pathway                          16      0.02557     KAT2B, MAP2K1, RAF1, FOXO1, MED13, ATP1A2, NRAS, NCOA1, NOTCH1, HIF1A, EP300, NCOA3, MAPK3, DIO1, PLCB1, AKT3
  Inflammatory mediator regulation of TRP channels           16      0.058489    IL1R1, ADCY1, PTGER4, CAMK2G, TRPA1, PRKCH, PRKCD, PPP1CB, GNAQ, MAPK12, PLA2G6, MAPK9, GNAS, PLCB1, CAMK2A, MAP2K6
  Osteoclast differentiation                                 16      0.058489    IL1R1, TNF, MAP2K1, CSF1, PPARG, FOS, TNFSF11, MAPK12, JUN, MAPK3, RAC1, MAPK9, PPP3CA, MAP2K6, AKT3, NFATC1
  Long-term potentiation                                     15      3.92E−04    ADCY1, MAP2K1, CAMK2G, RAF1, PPP1CB, NRAS, EP300, GNAQ, GRIA2, RPS6KA2, MAPK3, RAP1B, PPP3CA, PLCB1, CAMK2A
  Salmonella infection                                       15      0.0022      DYNC1I1, DYNC1LI2, ROCK2, ARPC1A, FOS, TJP1, MAPK12, ARPC2, JUN, MAPK3, RAC1, MAPK9, WASL, DYNC1H1, DYNC1I2
  Gap junction                                               15      0.005529    ADCY1, GNAI3, MAP2K1, RAF1, LPAR1, PRKG1, NRAS, TJP1, GNAQ, MAP3K2, MAPK3, GNAS, GUCY1B3, PDGFD, PLCB1
  Toll-like receptor signaling pathway                       15      0.02171     TNF, MAP2K1, MAP2K4, CXCL9, FOS, MAPK12, JUN, RAC1, MAPK3, MAP3K8, IL12A, MAPK9, MAP2K6, AKT3, TRAF3
  TNF signaling pathway                                      15      0.038777    TNF, DNM1L, MAP2K1, CSF1, MAP2K4, FOS, MAPK12, JUN, MAPK3, MAP3K8, CREB3L1, MAPK9, AKT3, MAP2K6, TRAF3
  Cell cycle                                                 15      0.093007    E2F2, E2F5, CDC14B, SMAD3, CDK7, CCNE1, CDKN1A, MAD2L1, EP300, RAD21, CCND2, YWHAQ, GADD45A, STAG2, TFDP1
  Amphetamine addiction                                      14      0.001509    CAMK2G, MAOB, GRIA4, PPP1CB, SIRT1, FOS, GRIA2, JUN, SLC18A2, CREB3L1, GNAS, PPP3CA, CACNA1D, CAMK2A
  Renal cell carcinoma                                       14      0.001509    MAP2K1, RAF1, HGF, PAK7, NRAS, CRKL, EP300, HIF1A, PAK4, JUN, RAC1, MAPK3, RAP1B, AKT3
  Fc gamma R-mediated phagocytosis                           14      0.011216    VAV3, MAP2K1, RAF1, ARF6, PRKCD, AMPH, ARPC1A, CRKL, ARPC2, MAPK3, RAC1, MARCKS, WASL, AKT3
  GABAergic synapse                                          14      0.014861    GABRG1, SLC38A3, ADCY1, GABRA2, GNAI3, GABRA1, SLC38A2, SLC6A1, GNB2, TRAK2, GNG10, ABAT, CACNA1D, NSF
  Long-term depression                                       13      0.002005    GNAI3, MAP2K1, RAF1, PRKG1, IGF1R, NRAS, GRIA2, GNAQ, PPP2CA, MAPK3, GNAS, GUCY1B3, PLCB1
  Progesterone-mediated oocyte maturation                    13      0.033215    ADCY1, GNAI3, MAP2K1, CPEB3, PDE3B, RAF1, IGF1R, MAD2L1, MAPK12, RPS6KA2, MAPK3, MAPK9, AKT3
  Colorectal cancer                                          12      0.008821    FOS, MAP2K1, JUN, MAPK3, RAC1, MAPK9, RAF1, SMAD3, LEF1, TCF7L2, AKT3, AXIN1
  Fc epsilon RI signaling pathway                            12      0.013779    NRAS, TNF, VAV3, MAPK12, MAP2K1, MAPK3, MAP2K4, RAC1, MAPK9, RAF1, AKT3, MAP2K6
  Melanoma                                                   12      0.018702    NRAS, IGF1R, E2F2, CDKN1A, FGF7, MAP2K1, MAPK3, RAF1, PDGFD, HGF, PTEN, AKT3
  Chronic myeloid leukemia                                   12      0.020602    NRAS, E2F2, CDKN1A, CBLB, CRKL, MAP2K1, MAPK3, CBL, RAF1, BCL2L1, RUNX1, AKT3
  Prolactin signaling pathway                                12      0.022641    NRAS, FOS, TNFSF11, MAPK12, MAP2K1, CCND2, MAPK3, MAPK9, RAF1, SOCS7, AKT3, CISH
  Pertussis                                                  12      0.024823    FOS, GNAI3, TNF, NOD1, MAPK12, JUN, MAPK3, IL12A, MAPK9, ITGB2, SERPING1, IL10
  Insulin secretion                                          12      0.06389     ADCY1, GNAQ, CAMK2G, CREB3L1, GNAS, ATP1A2, VAMP2, PLCB1, CAMK2A, CACNA1D, ADCYAP1, KCNMB2
  Circadian rhythm                                           11      6.68E−05    CRY2, NR1D1, BTRC, PRKAB2, PRKAB1, PER2, PER1, PER3, FBXW11, CLOCK, FBXL3
  Glioma                                                     11      0.025453    NRAS, IGF1R, E2F2, CDKN1A, MAP2K1, CAMK2G, MAPK3, RAF1, PTEN, CAMK2A, AKT3
  B cell receptor signaling pathway                          11      0.040119    NRAS, FOS, VAV3, MAP2K1, JUN, MAPK3, RAC1, RAF1, PPP3CA, AKT3, NFATC1
  Salivary secretion                                         11      0.069082    CD38, ADCY1, GNAQ, SLC12A2, ADRA1B, GNAS, GUCY1B3, ATP1A2, VAMP2, PLCB1, PRKG1
  Bacterial invasion of epithelial cells                     11      0.074081    ARPC1A, CAV2, CBLB, CAV1, CRKL, ARPC2, CBL, RAC1, WASL, CLTC, VCL
  Synaptic vesicle cycle                                     10      0.045841    ATP6V1C1, SYT1, CPLX2, SLC17A6, SLC18A2, ATP6V1B2, VAMP2, CLTC, UNC13C, NSF
  Pancreatic cancer                                          10      0.059074    E2F2, MAP2K1, MAPK3, RAC1, MAPK9, RAF1, RALA, SMAD3, BCL2L1, AKT3
  Arrhythmogenic right ventricular cardiomyopathy            10      0.092277    ACTN4, DMD, ITGA1, CACNB2, ACTN1, LEF1, CACNB4, ITGA4, CACNA1D, TCF7L2
  Renin secretion                                            10      0.092277    GNAI3, GNAQ, PTGER4, PDE3B, GNAS, GUCY1B3, PPP3CA, PLCB1, CACNA1D, ADCYAP1
  Vasopressin-regulated water reabsorption                   9       0.015204    DYNC1I1, DYNC1LI2, CREB3L1, GNAS, VAMP2, DYNC1H1, DYNC1I2, NSF, AQP2
  Endometrial cancer                                         9       0.04321     NRAS, MAP2K1, MAPK3, RAF1, LEF1, PTEN, TCF7L2, AKT3, AXIN1
  Acute myeloid leukemia                                     9       0.062572    NRAS, MAP2K1, MAPK3, RUNX1T1, RAF1, LEF1, RUNX1, TCF7L2, AKT3
  Malaria                                                    8       0.071947    LRP1, TNF, COMP, IL12A, ITGB2, HGF, SDC2, IL10
  Amyotrophic lateral sclerosis                              8       0.093164    DERL1, TNF, GRIA2, MAPK12, RAC1, BCL2L1, PPP3CA, MAP2K6
  Dorso-ventral axis formation                               7       0.010038    NOTCH1, MAP2K1, CPEB3, ETS1, ETS2, MAPK3, ETV6
  Nicotine addiction                                         7       0.082655    GABRG1, GABRA2, SLC17A6, GABRA1, GRIA2, CHRNA4, GRIA4
  Bladder cancer                                             7       0.090875    NRAS, E2F2, CDKN1A, MAP2K1, MAPK3, RAF1, HBEGF
  Thyroid cancer                                             6       0.067242    NRAS, MAP2K1, PPARG, MAPK3, LEF1, TCF7L2
  Sulfur metabolism                                          4       0.046731    SQRDL, PAPSS1, BPNT1, PAPSS2

Key modules analyses
--------------------

Based on information in the STRING database, all putative target genes constituted a PPI network that contained 1,360 nodes and 8,644 edges. The genes in the top three significant modules were further analyzed to evaluate their functions, and were involved in circadian rhythms, pathway in cancer, colorectal cancer, renal cell carcinoma, the ErbB signaling pathway, the wnt signaling pathway, vascular smooth muscle contraction, and long-term potentiation ([Fig. 4](#fig-4){ref-type="fig"}).

![Top 3 modules of the protein--protein interaction network.\
(A) Module 1; (B) the enriched pathways of module 1; (C) module 2; (D) the enriched pathways of module 2; (E) module 3; (F) the enriched pathways of module 3. The rectangle in brown, pink and red represent the genes in high FDR signaling pathway in each module, respectively.](peerj-07-8119-g004){#fig-4}

Validation of miRNA expression
------------------------------

Five miRNAs (miR-195, miR-338, miR-340, miR-374 and miR-669d), whose putative target genes were involved in both pathways in cancer and circadian rhythms were validated by qRT-PCR to confirm the results of miRNAs microarray analyses. We also analyzed the expression levels of these miRNAs over a 26 h period at 4 h intervals to obtain a broader view of the rhythmic expression of these miRNAs. These miRNAs were all upregulated and consistent with the microarray results ([Fig. 5](#fig-5){ref-type="fig"}). The expression levels of miR-195 and miR-340 retained a circadian manner in *Clock* mutant mice, despite the fact that their expression levels were greatly increased at all time points examined. The expression level of nr1d2 mRNA was down-regulated.

![Four miRNAs and three mRNAs expression profiles in WT and *Clock* mutant mice liver.\
(A, C, E and G) show the expression of five differently expressed miRNAs in WT and clock mutant mice over 26 h (4 h intervals) in a 12 L/12 D photoperiod by qRT-PCR. Data points (means of 5 biological replicates ± SEM) were normalized using U6. (B, D, F and H) Showed the relative fold change of five miRNAs analyzed by microarray and qRT-PCR at two time points, respectively. In (B, D, F and H), the *y*-axis represents the relative fold change, the value greater than zero represents the upregulation and the value less than zero represents the down-regulation. The relative miRNAs fold change of microarray was analyzed by the fold change (FC) of *Clock* mutant and wild type (WT) mouse with mathematical formula log~2~^FC(*Clock*)/FC(WT)^. The relative miRNAs fold change of qPCR was analyzed by the value after normalization to U6 with the comparative threshold method. If the value of *Clock* mutant more than WT mouse, the upregulation fold change was calculated with the formula 2^−ΔΔCt(*Clock*)^/2^−ΔΔCt(WT)^. The down-regulation fold change was considered when the value of *Clock* mutant less than WT mouse and analyzed by the mathematical formula 2^−ΔΔCt\ (WT)^/2^−ΔΔCt\ (*Clock*)^. (I, J and K) Showed the expression level of three putative target genes in WT and *Clock* mutant mice over 26 h (4 h intervals) in a 12 L/12 D photoperiod by qRT-PCR, data points (means of 5 biological replicates ± SEM) were normalized using *gapdh*. \**p* \< 0.05; \*\**p*\< 0.01.](peerj-07-8119-g005){#fig-5}

Discussion
==========

Circadian miRNAs involved in liver function represent a newly recognized level of the liver regulatory networks and the function of the biological clock. While many studies have demonstrated that CLOCK can regulate physiological processes in the liver by altering the expression of CCGs or physiological processes-related genes downstream of many cellular pathways, and microarray-based expression profiling of miRNAs in mouse liver at different time points has been used to identify circadian miRNAs, little is known about the molecular mechanism by which core clock genes coordinate with miRNAs to regulate liver function. In this study, we identified 104 miRNAs showing significant differential expression in the liver of *Clock* mutant mice (based on microarray analyses). We investigated their pathways and found that these miRNAs were mainly involved in cancer, PI3K-Akt signaling pathway, and the MAPK signaling pathway. Further investigation revealed that the hub genes were associated with circadian rhythms and pathway in cancer.

In our analyses, the liver-special miRNA, miR-122 (FC = 2.0009 at ZT2 and FC = 1.8112 at ZT14) was identified in liver tissue in absence of *Clock*, suggesting that our current strategy was appropriate for examining circadian miRNAs in the mouse liver although mature miRNAs did not show strong circadian oscillation. Furthermore, 14 miRNAs were altered at both analyzed time points, including miR-100, miR-195, miR-221, miR-338-5p, miR-34a, miR-340-3p, miR-374, miR-423-5p, miR-429, miR-455, miR-497, miR-532-5p, miR-669d and miR-802. Notably, except for miR-532-5p and miR-669d, the other miRNAs were previously identified to be involved in liver function. However, previous studies have only determined the association between these miRNAs and liver function, while the impact of circadian rhythms on miRNAs expression in the liver has not been examined. Thus, the identification of CLOCK-regulated miRNAs and their function in the circadian rhythm provides new insights.

Among the miRNA-mRNA pairs, four miRNAs directly targeted core circadian clock genes. This indicates that miRNAs may play a vital role in regulating circadian rhythms through core circadian clock genes. miR-34a targets *Per1* and is rhythmically expressed in cholangiocarcinoma cells and H69 cells, and its inhibition decreases proliferation, migration and invasion in cholangiocarcinoma cells ([@ref-6]). Coupled with those results, our study suggests that the differentially expressed Clock-regulated miRNAs would construct a strong correlation network among miRNA expression, circadian rhythms, and liver function. Interestingly, although the expression levels of miR-100, miR-195, miR-221, miR-34a, miR-497 and miR-802 did not significantly differ at ZT2 and ZT14, they have been found to regulate hepatocellular carcinoma metastasis, hepatic insulin resistance, liver disease and other maladies. These results suggest that the miRNAs that do not show significant circadian oscillation are also worth of study.

Numerous studies have demonstrated that miRNAs might play important and extensive roles in liver development and regeneration in addition to contributing to or preventing chronic liver disease by directly or indirectly targeting cell cycle, proliferation or apoptosis genes. [@ref-28] found that miR-100 directly inhibits the expression of isoprenylcysteine carboxyl methyltransferase (ICMT) and ras-related C3 botulinum toxin substrate 1 (Rac1) by binding to their 3′ UTRs, and represses metastasis of hepatocellular carcinoma (HCC) cells. In another study, miR-100 suppressed the expression of mTOR and IGF-1R in HCC cells by binding to their 3′ UTR, and knockdown of mTOR or IGF-1R phenocopied the pro-autophagy effects of miR-100 ([@ref-5]). In our study, we also showed that Rac1 was regulated by miR-100. Although the suppression of IGF-1R by miR-100 was not observed, we found that Igf-1R was regulated by miR-340-3p. These differences may be due to the different prediction software used. IGF‑1R is a key component of the IGF axis that promotes cell proliferation, migration, and transformation. Increased expression of IGF-1R in HCC is closely associated with tumor progression ([@ref-23]). We predicted that miR-340-3p may inhibit proliferation in HCC cells by reducing IGF-1R levels. In a previous study, the target genes of miR-195 and miR-497 played important roles in increasing tumor life span, inhibiting tumor growth, and regulating cell cycle in HCC, and suppressing the growth of xenograft tumors in nude mice ([@ref-4]). Consistent with these studies, the miR-195 targeting *Pcmt1* or *Cbx4* or *Btrc* or *Phf19* or *Ccne1*, and miR-497 targeting *Btrc* pairs were all observed in our results.

Gene co-expression network analysis is an essential tool for identifying the hub genes regulated by miRNAs. In our study, among the three modules screened using Cytoscape, the module pathways were mostly associated with the circadian rhythms. Studies of circadian rhythms provide important insights into the role of the circadian clock in liver physiology at the transcriptional level. However, recent proteomics studies have found that the levels of some metabolic enzymes cycle, although their transcript levels remain relatively constant throughout the day, indicating that post-transcriptional mechanisms might also be involved in circadian regulation of liver functions. Our results showed that miR-340-3p, miR-669d, miR-374 and miR-338-5p could directly target circadian genes (miR-340-3p targeting *Clock*, *Per1*, *Cry2*; miR-669d targeting *Per2*; miR-374 targeting *Per3*; miR-338-5p targeting *Nr1d1*), further supporting this idea. The other main pathway was pathway in cancer, and the genes in this pathway can impact tumor cell proliferation (PPARG, RAF1), regulate hepatic glucose and lipid metabolism (FOXO1), and decrease the viability and invasiveness of HCC cells (RALA) ([@ref-3]; [@ref-19]; [@ref-9]; [@ref-13]; [@ref-22]). This suggests that at the molecular level, CLOCK-regulated miRNAs may be involved in cancer initiation or progression by directly controlling cell proliferation, cell invasion, or metabolism-related genes in the mouse liver.

In summary, we identified changes in miRNA expression in *Clock* mutant mouse liver, and these CLOCK-regulated miRNAs had the ability to take part in liver function. Our results provide additional evidence to support the expanding research linking circadian rhythms dysfunction, miRNA expression, and liver function. Understanding the regulatory mechanism of *Clock* in the liver at the post-transcriptional level is critical importance for further highlighting the role of circadian miRNAs in peripheral organ or tissue. Our study focused only on 14 differentially expressed miRNAs, and analyses of the remaining miRNAs are necessary to fully understand the impact of circadian miRNAs on liver function and to identify biomarkers of liver disease.

Conclusion
==========

Our miRNA profile analyses identified a number of miRNAs that may be regulated by CLOCK and revealed these miRNAs linked to liver function. The functional roles of these miRNAs may affect the various physiological processes of the liver, and these data provide a reference for better understanding potential regulatory mechanisms in the liver.
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